trending Market Intelligence /marketintelligence/en/news-insights/trending/zmzi3cl58kfj01gbqje4ea2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Nabriva, Roivant ink license deal for bacterial pneumonia drug in China

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Nabriva, Roivant ink license deal for bacterial pneumonia drug in China

Irish pharmaceuticals company Nabriva Therapeutics PLC and privately held Roivant Sciences will collaborate to develop and commercialize the antibiotic Lefamulin in the Greater China region.

Lefamulin met its main goal in a late-stage trial as a treatment of community-acquired bacterial pneumonia and is being studied in another phase 3 clinical trial, with results expected in the spring.

As a part of the agreement, Hong Kong-based Roivant gained an exclusive license to develop and commercialize the drug in the Greater China region, specifically the People's Republic of China, Hong Kong, Macau and Taiwan.

Roivant's affiliate will be solely responsible for all clinical development and regulatory filings necessary to secure approval in the covered territories.

In return, Dublin-based Nabriva will receive a $5 million upfront and will be eligible for up to about $90 million in additional payments tied to certain regulatory and commercial milestones.

The company will also receive royalties on sales upon approval in the covered territories.

Based on the results of the second trial, Nabriva plans to seek U.S. approval of the drug in the second half of 2018.